SOURCE: Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals, Inc.

February 03, 2009 11:07 ET

Molecular Insight Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference

CAMBRIDGE, MA--(Marketwire - February 3, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that John W. Babich, Ph.D., Chief Executive Officer, President and Chief Scientific Officer of Molecular Insight Pharmaceuticals, Inc., will present at the 11th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York, New York. Dr. Babich will review Molecular Insight's robust pipeline of innovative molecular imaging radiopharmaceuticals and molecular radiotherapeutic candidates on February 10, 2009 at 1:45 PM, Eastern Time, in the Louis XVI Room.

The Molecular Insight company presentation will be webcast live at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=**MIPI&item_id=2079568 and will be archived for one year. It will also be available in the Investor Relations section of the Molecular Insight Pharmaceuticals website at www.molecularinsight.com.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The Company is focused on discovering, developing, and commercializing innovative molecular imaging radiopharmaceuticals and targeted molecular radiotherapeutics with initial applications in the areas of cardiology and oncology. Molecular Insight's lead molecular imaging radiopharmaceutical product candidate, Zemiva™, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. The Company's imaging candidate, Trofex™, is in development for the detection of metastatic prostate cancer. Molecular Insight's lead molecular radiotherapeutic product candidates, Azedra™ and Onalta™, are being developed for detection and treatment of cancer. In addition, the Company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. For more information, visit www.molecularinsight.com.

Contact Information

  • Contact:
    Deborah S. Lorenz
    Senior Director
    Investor Relations and Corporate Communications
    Molecular Insight Pharmaceuticals, Inc.
    (617) 871-6667
    dlorenz@molecularinsight.com